Walgreens' DEI Employment Practices: What the Company's Own Documents Show — and What They Mean for Employees

Published August 27, 2026 · Last updated August 27, 2026 · By Fett Law — Michigan Employment Discrimination Attorneys

Key facts

Did Walgreens tie bonuses to diversity targets?

The mechanism had a name. Walgreens Boots Alliance called it the Leadership Accountability Model, and described it in its own DEI report:

"through our Leadership Accountability Model, we now tie a portion of bonus incentives to our performance on our diversity goals."

— Walgreens Boots Alliance, Inc., 2020–21 Diversity, Equity & Inclusion Report ("DE&I at WBA") (source)

The company put the same sentence in its September 29, 2021 press release announcing the report, describing the "Leadership Accountability Model, which ties a portion of incentive pay for bonus-eligible employees to the company's performance on diversity goals" (announcement).

The size of that portion is stated in the report's accountability section:

"the corporate DE&I goal, which will account for 10 percent of fiscal 2021 WBA bonus criteria"

— Walgreens Boots Alliance, Inc., 2020–21 Diversity, Equity & Inclusion Report ("Holding Ourselves Accountable") (source)

How far down the organization that reached was described by the executive who ran the program. Carlos Cubia, then Senior Vice President and Global Chief Diversity, Equity and Inclusion Officer of Walgreens Boots Alliance, put it this way in a published interview:

"If you get a bonus in this company, I don't care what level you are, you have DEI goals that you're responsible for either directly or indirectly, and that is 10% of our annual bonus is related to DE&I"

— Carlos Cubia, SVP and Global Chief Diversity, Equity and Inclusion Officer, Walgreens Boots Alliance, interview published June 14, 2022 (source)

Shareholders were told the same thing in the company's proxy statements. The proxy filed in 2021 described "the addition of objective diversity, equity and inclusion (DEI) goals" to the incentive program and explained the rationale: "DEI is a critical objective for our business and we believe incorporating a metric into our incentive programs demonstrates our commitment to diversity, equity and inclusion throughout our business" (DEF 14A, 2021).

The metric was then restructured rather than removed. The proxy filed in 2022 records:

"We repositioned and expanded our DEI annual bonus metrics into 'Health Equity' metrics beginning in fiscal 2023, which includes new disability representation and environmental sustainability focused goals"

"We are the first company in the S&P 500 to include disability representation as a separate, standalone metric within its fiscal 2023 annual cash incentive plan."

— Walgreens Boots Alliance, Inc., Proxy Statement (DEF 14A), filed 2022 (source)

The health equity goal was still being measured two years later. The proxy filed in 2024 reports: "While the MIP did not pay out, we are very proud to announce that we exceeded target-level performance against our fiscal 2024 health equity goal" (DEF 14A, 2024). The fiscal 2025 performance-share goals disclosed in that same document are adjusted earnings per share, free cash flow and a relative total-shareholder-return modifier — no diversity or health-equity component appears.

What this meant operationally is direct. For at least fiscal 2021 and 2022, a defined slice of the bonus pool at a company employing hundreds of thousands of people moved with how the company performed on demographic representation. That gave every bonus-eligible manager a financial interest in the demographic composition of the people they hired and promoted. Whether it changed any particular decision is a fact question — and the managers, recruiters and HR staff who administered the goals are the people who would know.

Did Walgreens require diverse candidate slates and interview panels?

The company's own DEI report describes the requirement in mandatory terms:

"requiring diverse candidate slates and diverse interview panels for open roles, have enhanced our ability to reach and attract more diverse talent."

— Walgreens Boots Alliance, Inc., 2020–21 Diversity, Equity & Inclusion Report ("DE&I at WBA") (source)

The scope was global and tied to leadership hiring:

"we implemented diverse slates and interview panels for all leadership positions globally"

"we introduced leadership accountability goals by segment and global function"

— Walgreens Boots Alliance, Inc., 2020–21 Diversity, Equity & Inclusion Report ("Building Talented & Diverse Teams") (source)

Most consequentially, the slate and panel practice was itself one of the measured goals inside the bonus structure described in the previous section. Among the corporate goals the company listed under its accountability heading:

"Ensure 100% compliance of diverse candidate slates and diverse interview panels for leadership roles"

— Walgreens Boots Alliance, Inc., 2020–21 Diversity, Equity & Inclusion Report ("Holding Ourselves Accountable") (source)

The same document lists as a stated priority "evolved leadership accountability: strengthen supporting talent practices (diverse slates, diverse interview panels) and link to pay" — the company's own description of the two practices operating together.

For an applicant, the practical effect of a slate rule is invisible from the outside and decisive from the inside. If a requisition could not proceed until the slate satisfied a demographic condition, then the composition of the slate — not only the merits of each individual candidate — was part of what determined who reached an interview and who did not. A published requirement does not by itself decide any individual case. What matters legally is whether the demographic condition changed an actual decision. Recruiters, hiring managers and HR business partners who worked leadership requisitions at Walgreens between 2020 and 2024 are the people best placed to know whether it did.

Did Walgreens set racial or gender representation goals?

The goals are stated in the accountability section of the company's own DEI report:

"Increase representation of women globally by 3 percentage points over prior year"

"Increase representation of underrepresented racial and ethnic groups in U.S. leadership roles by 2 percentage points over prior year"

"Spend $500 million with Tier 1 diverse suppliers in the U.S., an increase of approximately $53 million"

— Walgreens Boots Alliance, Inc., 2020–21 Diversity, Equity & Inclusion Report ("Holding Ourselves Accountable") (source)

The company had announced the same two representation targets a year earlier, on September 17, 2020, framing them as leadership commitments effective with the fiscal year beginning September 1, 2020: a 3% increase of women in leadership across Walgreens Boots Alliance, and a 2% increase of people of color in leadership in Retail Pharmacy USA (announcement). Stefano Pessina, then Chief Executive Officer, was quoted in that release: "Diversity and inclusion are core to our purpose of helping people live healthier, happier lives."

These were not goals that sat on a page. By the company's own account they were scored, and the score moved money. Mr. Cubia described the first year's outcome in the June 2022 interview: the company hit four of its five diversity goals, producing a net payout above 100%, and fell short only on the women-in-leadership target, landing a little over two percentage points against the three-point goal.

In plain terms: for at least fiscal 2021 and 2022, Walgreens set specific numeric increases in the share of women and of underrepresented racial and ethnic groups in defined populations, measured performance against them, and connected that performance to bonus pay. Employees who competed for leadership roles during that window — and the executives and HR professionals who reported on the numbers — are the people who would know how the targets were translated into instructions further down.

Did Walgreens run programs restricted by race or sex?

This section is included because its answer is largely a negative one, and the difference matters. In the IBM matter, the Justice Department's allegations included training, mentoring and leadership programs whose eligibility was "limited on the basis of race or sex." Walgreens' published descriptions of its internal programs do not match that pattern in the documents we reviewed.

The company's DEI report names business resource groups organized around protected characteristics — groups for women, for Latino professionals, an Asian Connect group, and an African American leadership group — each with executive sponsorship. Naming a group after a community is not the same as closing it to everyone else, and we found no Walgreens document in any year stating that any of these groups was closed to employees outside its named community. We say so plainly rather than treating the group names as evidence of a restriction they do not state. The report's other named programs — the Retail Employees with Disabilities Initiative and the HERO program, which serves veterans — turn on disability and veteran status, not on race or sex.

The one item with a demographic criterion in its written terms is external and student-facing. The Walgreens Diversity & Inclusion Excellence Scholarship, offered through pharmacy schools, lists as one of its criteria that a "student embraces diversity and promotes diversity and inclusion initiatives on campus or represents an underrepresented group in pharmacy" (program listing). That is a disjunctive criterion — a student who is not a member of an underrepresented group can qualify on the first branch — and it is a scholarship rather than an employment decision. Some school-level listings of Walgreens pharmacy scholarships have carried harder language, including a "must be a minority" line (listing); those are third-party descriptions of school-administered awards and should be verified against the awarding school's own terms before any weight is put on them.

We state this marker as we found it. If you participated in a Walgreens internal leadership, mentoring or sponsorship program that did apply a race or sex eligibility condition in practice, that is exactly the kind of first-hand knowledge the public record cannot supply.

How Walgreens' DEI program changed, 2019–2026

Why these practices matter legally

Two recent Supreme Court decisions changed the landscape for these claims. In Muldrow v. City of St. Louis (2024), the Court held that an employee challenging a discriminatory job transfer need show only some harm to the terms or conditions of employment, not a "significant" disadvantage. In Ames v. Ohio Department of Youth Services (2025), a unanimous Court rejected the rule — previously applied in several federal circuits — that a majority-group plaintiff must produce extra "background circumstances" evidence before a discrimination claim can proceed. Separately, 42 U.S.C. § 1981 prohibits race discrimination in the making and enforcement of contracts, including employment relationships, and carries a four-year window with no agency filing requirement. (Title VII, 42 U.S.C. § 2000e-2.)

The False Claims Act route for federal contractors. On April 10, 2026, the U.S. Department of Justice announced that IBM would pay $17,077,043 to resolve False Claims Act allegations that it failed to comply with anti-discrimination requirements in its federal contracts — the first settlement under the DOJ's Civil Rights Fraud Initiative. In August 2026 the government resolved a second, larger matter: under a settlement agreement effective August 21, 2026, five Deloitte entities agreed to pay $21,500,000, of which $9,995,000 was restitution, covering conduct from January 1, 2017 through the settlement date. The certification hook is specific — Title VII as incorporated into federal contracts and FAR clause 52.222-26 — and the government's theory reached not only what Deloitte certified to its contracting agencies but what it "publicly represented" about its compliance. The agreement adds a second and independent theory: that Deloitte "allocated costs to its federal government contracts relating to these practices and sought payment and reimbursement under its federal government contracts for such costs." The whistleblower was paid $4,300,000. Both settlements resolved allegations only, with no determination of liability, and Deloitte denies the conduct.

Why that matters for a company in Walgreens' position is the overlap in the conduct described. The practices the Justice Department identified in the IBM matter were a diversity modifier tying bonus compensation to demographic targets, "diverse interview slates," race and sex demographic goals for business units, and programs whose eligibility was "limited on the basis of race or sex" (DOJ press release). Three of those four categories — the bonus linkage, the diverse slates, and the numeric demographic goals — are described in Walgreens' own documents. The Deloitte agreement describes the same architecture in more detail: "non-public race and sex-based workforce composition goals for business units," progress flagged "in green, yellow, or red," senior personnel "evaluated, in part, based on their contributions to helping Deloitte achieve its workforce composition goals," candidates "identified by race and sex in a spreadsheet," and two programs "where eligibility to participate was limited on the basis of race and sex."

To be clear about what is and is not established: no court or agency has found that Walgreens' practices violated any law, and the IBM and Deloitte settlements each resolved allegations without any admission or determination of liability. But practices like those documented above — a stated requirement that leadership candidate slates and interview panels satisfy demographic conditions, numeric annual increases in the representation of women and of underrepresented racial and ethnic groups, and bonus pay that moved with performance against those numbers — are precisely the categories that can give rise to liability under Title VII and § 1981, and, for companies doing business with the federal government, potential False Claims Act exposure. For the complete framework — the four illegal DEI practice categories and when you can sue — see our guide, Is DEI Illegal? 4 Illegal DEI Practices & When You Can Sue.

Were you affected by these practices at Walgreens?

If you worked at Walgreens, Walgreens Boots Alliance or Walgreen Co. — or applied there — between 2020 and 2025, the documented practices above may have touched your career in ways worth examining:

• You applied for a leadership role and never reached an interview, or were interviewed and not selected, during a period when the company had implemented diverse slates and interview panels "for all leadership positions globally" and made 100% compliance with that requirement one of its scored corporate goals.
• You were passed over for a promotion into leadership while the company was working against published targets to raise the share of women globally by three percentage points a year and the share of underrepresented racial and ethnic groups in U.S. leadership by two percentage points a year.
• You were a recruiter, hiring manager, or HR business partner with first-hand knowledge of how the slate and panel requirement was applied to particular requisitions — whether a role was held open, a candidate added, or a decision changed to satisfy it.
• You were a bonus-eligible manager or executive whose own compensation carried a diversity component, or who saw how the corporate goal was cascaded into segment and function targets and then into instructions to hiring teams.
• You worked in compensation, finance or DEI reporting and saw how performance against the representation goals was measured, reported and translated into the bonus payout.

There is a separate question worth asking if your work touched Walgreens' federal business. The False Claims Act's qui tam mechanism lets an individual bring a claim on the government's behalf, and potentially share in any recovery, where a company certified compliance with federal anti-discrimination requirements while doing something else — the theory the Justice Department used against IBM and then Deloitte. Whether any Walgreens entity made certifications of that kind during the relevant period is a fact-specific question the public record does not answer; it is the sort of thing an insider may know. Qui tam complaints are filed under seal, so a whistleblower's identity is initially protected. Both Title VII and the False Claims Act prohibit retaliation against people who assert their rights or report violations.

A federal settlement is not a substitute for your own claim: when the Justice Department resolved the Deloitte matter, it expressly preserved the EEOC's right to pursue charges alleging the very same conduct, and preserved individual liability. Nothing about that settlement compensated a single employee or applicant.

If any of these fits, it costs nothing to find out where you stand — meet our DEI discrimination lawyers, or start below.

What could a claim against Walgreens be worth?

Whistleblower rewards under the False Claims Act

Under 31 U.S.C. § 3730(d), a qui tam relator receives 15–25% of the government's recovery when the Department of Justice intervenes, and 25–30% when the relator proceeds without intervention. The Deloitte settlement supplies a paid benchmark rather than a projection: the relator received $4,300,000 — exactly 20% of a $21,500,000 recovery. That settlement also shows why False Claims Act exposure outruns the money actually lost. Of the $21.5 million, $9,995,000 was restitution — roughly the government's single damages — so the resolution came to about 2.15 times the actual loss, because FCA recoveries are built on multiplied damages plus per-claim penalties. As a second illustration, arithmetic alone: an intervened case resolving at IBM's $17,077,043 would pay a relator roughly $2.6–$4.3 million. A contractor with a larger federal book or a longer conduct period could produce a materially larger number.

Damages in individual discrimination cases

Back pay and front pay are uncapped under Title VII. Compensatory and punitive damages under Title VII are capped by employer size — $300,000 for employers with more than 500 employees, the bracket Walgreens occupies many times over — but race claims under 42 U.S.C. § 1981 carry no damages caps at all, which is one reason race discrimination cases are often pleaded under it. Several state civil-rights statutes are likewise uncapped, including Illinois' Human Rights Act, which governs the company's Deerfield-area corporate workforce, and Michigan's Elliott-Larsen Civil Rights Act. Prevailing plaintiffs generally recover attorney's fees on top. For a sense of what employment discrimination cases can produce, Fett Law's own results include a $10.5 million race and age discrimination class action against Ford Motor Company, a $2 million disability harassment result, and a $1.6 million racial harassment result. Prior results do not guarantee a similar outcome.

Class action potential

Class actions are built on a single policy applied to many people — and a requirement that every leadership slate and interview panel satisfy a demographic condition is, by construction, companywide. Walgreens described it as implemented "for all leadership positions globally" and made 100% compliance a scored corporate goal. Historic employment-discrimination class settlements show the range such cases can reach: Coca-Cola paid $192.5 million (2000), Texaco $176.1 million (1996), and Novartis $175 million (2010) to resolve class claims.

Every case depends on its own facts — these figures show the range the law makes possible, not a promise of any outcome. The fastest way to learn where your situation falls is to start a confidential intake or request a free consultation.

Sources